A gleam of gastric cancer
Conditions
Interventions
treatment group:Apatinib Mesylate Tablets 250mg, Oxaliplatin 130mg/m2, Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/m2/d, 14 days
Control group:Oxaliplatin 130mg/m2, Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/m2/d, 14 days
Sponsors
Jiangsu Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years old, men or women; 2. advanced gastric cancer or gastroesophageal junction adenocarcinoma by pathological histology and/or cytology diagnosis and outside having stomach measurable lesions (10 mm or higher spiral CT scan, RECIST 1.1 standard); 3. The ECOG score 0 to 2 points; 4. The expected lifetime acuity in March; 5. Major organs function is normal, that meet the following criteria: (1) the blood routine examination standards must be in accordance with (14 days without blood transfusion and adjuvant therapies, unused and other hematopoietic stimulating factor (g-csf) correct): HB 90 g/L or higher; the ANC acuity 1.5 x 10^9/L; PLT acuity 80 x 10^9/L; (2) and biochemical examination must be in accordance with the following criteria: TBIL 45 ml/min (Cockcroft - Gault formula); 6. The doctor thinks treatment can bring benefit; 7. Patients can understand and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Confirmed the apatinib for the piece and/or its accessories allergies; 2. Pregnant or lactating women; 3. The apatinib for patients with contraindications(active bleeding, ulcer, bowel perforation, intestinal obstruction, hand within 30 days after operation, uncontrolled hypertension drugs, grade III - IV cardiac insufficiency, disabled) in patients with severe liver and kidney function; 4. Tumor tissue in patients with immunohistochemical or FISH testing positive for its Her - 2; 5. The doctor considered a person not eligible to be included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactShu Yongqian
Jiangsu province people's hospital
Outcome results
None listed